Mateon Therapeutics is a biopharmaceutical company that looks to develop anti-vascular therapeutics for patients with cancer and optical diseases. The company was founded in 1988 in San Francisco, California, United States.
The company is developing anti-angiogenic agents, of which, some are approved by the FDA and used globally to treat cancer, as well as vascular disrupting agents for the same purpose.
With the outbreak of COVID-19, Mateon Therapeutics has launched an antiviral response program to combat the disease caused by the novel coronavirus. They are exploring therapeutic and artificial intelligence platforms to develop new coronavirus treatments. They are also advancing their efforts to fight the virus and any rare tropical diseases that may come in the near future. Mateon Therapeutics claims to have discovered some antiviral candidates and has partnered with researchers to further the progress of these candidates.
The company has also established a division for the approach of developing COVID-19 treatments as well as other future zootonic outbreaks.
COVID-19 - Oncotelic Inc- a TGF ImmunoOncology Company
Mateon launches antiviral programme focussed on Covid-19
March 3, 2020
Mateon Therapeutics | Crunchbase
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- COVID-19COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the World Health Organization.